Dual Incretin Agonist (GLP-1 & GIP) | Advanced Weight Loss & Glycaemic Control Peptide | For Research Use Only

Tirzepatide is a cutting-edge synthetic peptide that acts as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism offers a superior approach to appetite regulation, blood glucose control, and body weight reduction compared to GLP-1 monotherapies such as Semaglutide.

Tirzepatide – 60mg is ideal for advanced metabolic research, providing long-acting incretin mimetic effects with high efficacy in obesity, type 2 diabetes, and insulin resistance models.

🔍 Key Features

• Dual Agonist: GLP-1 and GIP Receptor Activation

• Reduces Appetite and Food Intake

• Improves Glucose Tolerance and Insulin Sensitivity

• Promotes Weight Loss and Fat Oxidation

• Outperforms GLP-1 Monotherapy in Preclinical and Clinical Studies

• Supports Once-Weekly Research Protocols

⚙️ Compound Details

• Peptide Name: Tirzepatide

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₀N₆₀O₆₅

• Molecular Weight: ~4813.45 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 60mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C in a dark, dry environment

• Reconstitution: Use 1–2ml sterile bacteriostatic water

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat, direct sunlight, and multiple freeze-thaw cycles

⚠️ For Research Use Only

Tirzepatide – 60mg is provided exclusively for scientific and laboratory research. It is not for human consumption, therapeutic use, or diagnostic purposes.